Continuation Sessions of Mindfulness-Based Cognitive Therapy (MBCT-C) vs. Treatment as Usual in Late-Life Depression and Anxiety: An Open-Label Extension Study.

Autor: Dikaios E; McGill Meditation and Mind-Body Medicine Research Clinic (MMMM-RC) and GeriPARTy Research Group, Jewish General Hospital, Montreal, Canada., Escobar S; McGill Meditation and Mind-Body Medicine Research Clinic (MMMM-RC) and GeriPARTy Research Group, Jewish General Hospital, Montreal, Canada.; Department of Psychiatry, McGill University, Montreal, Canada., Nassim M; McGill Meditation and Mind-Body Medicine Research Clinic (MMMM-RC) and GeriPARTy Research Group, Jewish General Hospital, Montreal, Canada., Su CL; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Quebec, Canada., Torres-Platas SG; McGill Meditation and Mind-Body Medicine Research Clinic (MMMM-RC) and GeriPARTy Research Group, Jewish General Hospital, Montreal, Canada.; Department of Psychiatry, McGill University, Montreal, Canada., Rej S; McGill Meditation and Mind-Body Medicine Research Clinic (MMMM-RC) and GeriPARTy Research Group, Jewish General Hospital, Montreal, Canada.; Department of Psychiatry, McGill University, Montreal, Canada.
Jazyk: angličtina
Zdroj: International journal of geriatric psychiatry [Int J Geriatr Psychiatry] 2020 Oct; Vol. 35 (10), pp. 1228-1232. Date of Electronic Publication: 2020 Jul 03.
DOI: 10.1002/gps.5360
Abstrakt: Objectives: Mindfulness-based cognitive therapy (MBCT) is a novel treatment for depression. Our published randomized controlled trial shows that MBCT improves symptoms of late-life depression (LLD) and anxiety (LLA). We now examine whether continuation sessions of MBCT (MBCT-C) can prevent LLD/LLA symptom recurrence.
Methods/design: Following an 8-week MBCT intervention, we compared patients who attended open-label weekly 1-hour MBCT-C for another 26 weeks (n = 10) vs those who did not (n = 17) for change in depressive and anxiety symptoms.
Results: While there were no significant differences between groups on depressive or anxiety symptom severities between 8- and 34- weeks (Cohen's d = 0.045), we observed a small clinical effect of MBCT-C on symptoms of anxiety (d = 0.29).
Conclusions: These preliminary results suggest that MBCT-C may be somewhat beneficial for symptoms of LLA, but not for LLD. Healthcare providers should consider what is clinically feasible before investing time and resources into MBCT-C in older adults with depression and/or anxiety.
(© 2020 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: